Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Understanding Glaucoma Immunopathology by Building Retina-on-a-Chip
Author Affiliations & Notes
  • Qin (Maggie) Qi
    Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Kevin Liu
    Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Eunice Park
    Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Fiona Duong
    Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Dongfeng Chen
    Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Kin-Sang Cho
    Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Maximilian Braun
    Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Qin (Maggie) Qi None; Kevin Liu None; Eunice Park None; Fiona Duong None; Dongfeng Chen None; Kin-Sang Cho None; Maximilian Braun None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 937. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qin (Maggie) Qi, Kevin Liu, Eunice Park, Fiona Duong, Dongfeng Chen, Kin-Sang Cho, Maximilian Braun; Understanding Glaucoma Immunopathology by Building Retina-on-a-Chip. Invest. Ophthalmol. Vis. Sci. 2024;65(7):937.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Understanding the pathogenesis of glaucoma and evaluating therapeutic solutions in vitro require a systematic platform capable of mimicking the complex in vivo environment. In the presence of an intact inner blood-retinal barrier(iBRB), transendothelial migration of T cells is restricted. Emerging evidence suggests that this mechanism is compromised in glaucoma, but a conventional in vitro model of two-dimensional cell cultures fails to capture such multi-tissue pathophysiology. Recent progress in microfluidics-based cell culturing or “organ-on-a-chip” has made it possible to reproduce organ-level human physiology and better mimic various disease features found in vivo. This presentation will introduce a "retina-on-a-chip" system consisting of microglia, retinal endothelial cells and T cells to study the cascading effect of T-cell-microglia crosstalk across the iBRB during glaucoma progression. The specific roles of three cytokines (CCL3, CCL4 and IL-6) related to microglia activation will also be elucidated.

Methods : We construct a multi-compartment microfluidic device, with retinal endothelial cells cultured in one compartment to form a confluent monolayer mimicking the iBRB and cytokines or activated microglia housed in an adjacent interconnecting compartment (n=3 chips per group). We perfuse fluorescently labeled CD 4+ T cells into the retinal endothelial compartment and track infiltration events over 24 hours under a live cell microscope. In the end, we collect supernatant and T cells from both compartments for further chracterization. We also perform immunostaining of microglia and retinal endothelial cells on the chip. To examine iBRB barrier properties due to immunoregulation, we perfuse FITC-dextran to measure the iBRB permeability through quantitative imaging.

Results : Over 24 hours, we observe significant T cell infiltration under the influence of cytokines, confirming a compromised iBRB and a cascade of immune regulations relevant to glaucoma progression.

Conclusions : Our microfluidic model elucidates the role of microglia in regulating T cell infiltration in greater detail compared to animal models. Thus, it has great potential to become a low-cost platform technology to study fundamental disease mechanisms and accelerate drug development to benefit glaucoma research.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×